Free Trial
Daniel Brims

Daniel Brims Analyst Performance

Senior Biotech Research Analyst at Lake Street Capital

Daniel Brims is a stock analyst at Lake Street Capital in the healthcare sector, covering 8 publicly traded companies. Over the past year, Daniel Brims has issued 9 stock ratings, including and buy recommendations. While full access to Daniel Brims' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniel Brims' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
15 Last 12 Years
Buy Recommendations
100.00% 15 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%15 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
87.5% of companies on NASDAQ
7 companies
NYSE
12.5% of companies on NYSE
1 company

Daniel Brims, an analyst at Lake Street Capital, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
8 companies
100.0%

Daniel Brims of Lake Street Capital specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
6 companies
75.0%
PHARMACEUTICALS
2 companies
25.0%

Daniel Brims' Ratings History at Lake Street Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Rezolute, Inc. stock logo
RZLT
Rezolute
10/6/2026Boost Price Target$4.38$12.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
9/30/2026Initiated Coverage$4.09$9.00Buy
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
9/17/2026Initiated Coverage$7.61$41.00Buy
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
9/17/2026Initiated Coverage$7.10$41.00Buy
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
9/17/2026Initiated Coverage$54.16$149.00Buy
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
5/28/2026Initiated Coverage$5.60$45.00Buy
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5/28/2026Initiated Coverage$31.66$89.00Buy
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4/14/2026Initiated Coverage$8.72$23.00Buy
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4/14/2026Initiated Coverage$9.14$23.00Buy